Number of aberrant crypt foci associated with adiposity and IGF1 bioavailability.

What Was Tested

Researchers studied the intervention named in the title in this randomized controlled trial publication.

Dysregulation of the insulin-like growth factor (IGF) system, a common consequence of adiposity-induced insulin resistance, may be a key underlying mechanism linking excess body weight with colon cancer.

Evidence has been derived from studies of cancer and polyps.

Who Took Part

The abstract describes 26 patients taking part.

By PubMed's age tags, the people studied were adults, both men and women.

The researchers randomly selected 26 patients with sex-specific elevated waist-hip-ratio (WHR) and 26 with normal values from a series of 150 patients seeking routine colonoscopy at the University of Connecticut Health Center.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Cross-sectional analyses were performed of ACF number (<5, > or = 5) in relation to total IGF1, IGF-binding protein-3 (IGFBP3), insulin, body mass index (BMI), WHR and waist circumference (WC).

Visualized ACF in the 20 cm of the distal colon were counted using advanced endoscopic imaging.

What Was Measured

PubMed files the paper under topics including Adiposity, Body Mass Index, Colonic Neoplasms, Colonic Polyps, Cross-Sectional Studies, Insulin-Like Growth Factor I and Waist Circumference.

What This Means in Plain Language

The paper is a randomized study in 26 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (Cancer causes & control : CCC), a journal based in Netherlands.

More context: all human trials.